Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Australian Clinical LabsASX:ACL -0.83%56 PB Ratio is 3.04 as of Aug. 01, 2026, which is 6% below its 10-year median of 3.24. GuruFocus rates ASX:ACL with a GF Score™ of 56/100 and a GF Value™ of A$3.06 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 194 Medical Diagnostics & Research companies, Australian Clinical Labs ranks worse than 68.04% on this metric.
The historical rank and industry rank for Australian Clinical Labs's PB Ratio or its related term are showing as below:
ASX:ACL'
s PB Ratio Range Over the Past 10 Years
Min: 2.17 Med: 3.24 Max: 15.27
Current: 3.03
During the past 6 years, Australian Clinical Labs's highest PB Ratio was 15.27. The lowest was 2.17. And the median was 3.24.
ASX:ACL's PB Ratio is ranked worse than 68.04% of 194
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.025
vs ASX:ACL: 3.03
During the past 12 months, Australian Clinical Labs's average Book Value Per Share Growth Rate was -6.90% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -8.80% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 28.00% per year.
During the past 6 years, the highest 3-Year average Book Value Per Share Growth Rate of Australian Clinical Labs was 54.20% per year. The lowest was -8.80% per year. And the median was 29.40% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Australian Clinical Labs's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Australian Clinical Labs PB Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Australian Clinical Labs's PB Ratio distribution charts can be found below:
* The bar in red indicates where Australian Clinical Labs's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Australian Clinical Labs (ASX:ACL) has a PB Ratio of 3.04 as of Aug. 01, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Australian Clinical Labs and its competitors. This is near median its historical median of 3.24. Over the past decade, Australian Clinical Labs' PB Ratio has ranged from 2.17 to 15.27. According to the industry distribution chart, Australian Clinical Labs ranks #132 out of 194 companies in the Medical Diagnostics & Research industry, placing it in the top 68%.
Is Australian Clinical Labs' PB Ratio too high?
Australian Clinical Labs' current PB Ratio of 3.04 is near median its 10-year median of 3.24. Over the past 10 years, this metric has ranged from a low of 2.17 to a high of 15.27. The Medical Diagnostics & Research industry median PB Ratio is 2.03. Australian Clinical Labs' value of 3.04 is 50.1% above this industry median. Based on the distribution chart, Australian Clinical Labs ranks #132 out of 194 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Australian Clinical Labs has a GF Score™ of 56/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Australian Clinical Labs' PB Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Australian Clinical Labs ranks #132 out of 194 companies for PB Ratio. This places Australian Clinical Labs in the lower half of its industry. The industry median PB Ratio is 2.03. Australian Clinical Labs' value of 3.04 is 50.1% above this benchmark. Historically, Australian Clinical Labs' own PB Ratio has ranged from 2.17 to 15.27 over the past decade. While the company's 10-year median is 3.24 vs. the industry median of 2.03, Australian Clinical Labs has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Diagnostics & Research company?
The median PB Ratio among Medical Diagnostics & Research companies is 2.03, based on 194 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Australian Clinical Labs's current PB Ratio of 3.04 is 50.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Australian Clinical Labs and its competitors. For the Medical Diagnostics & Research industry, the median PB Ratio is 2.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Australian Clinical Labs's current PB Ratio is 3.04, which is near median its own 10-year median of 3.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Australian Clinical Labs stock overvalued right now?
Based on GuruFocus' analysis, Australian Clinical Labs (ASX:ACL) is currently considered Modestly Undervalued. The stock's GF Value™ is A$3.06, compared to a current price of A$2.38 — trading 22.2% below its estimated fair value. The current PB Ratio is 3.04, which is near median its 10-year median of 3.24 and 50.1% above the Medical Diagnostics & Research industry median of 2.03. Australian Clinical Labs' overall GF Score™ is 56/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Australian Clinical Labs (ASX:ACL), the current PB Ratio is 3.04 as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Australian Clinical Labs (ASX:ACL) Overvalued in 2026?
Based on GuruFocus' analysis, Australian Clinical Labs stock appears to be undervalued.
The current stock price of A$2.38 is trading 22.2% below its estimated GF Value™ of A$3.06.
GuruFocus considers Australian Clinical Labs to be Modestly Undervalued.
Key valuation signals for ASX:ACL:
PB Ratio: 3.04 (near median its 10-year median of 3.24)
GF Value™: A$3.06 vs. price of A$2.38 (22.2% below fair value)
Industry Position: 50.1% above the Medical Diagnostics & Research median (#132 of 194)
No single metric tells the full story. See the ASX:ACL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Australian Clinical Labs is Australia's third-largest private pathology provider. ACL earns almost its entire group revenue from pathology services in Australia, which are mostly earned via the publicly funded health Medicare system. ACL is well established in the states of Western Australia, South Australia, Victoria, and the Northern Territory.
56GF Score
Get the complete analysis for ASX:ACL
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:ACL has been successfully added to your 
